Smooth muscle apoptosis during vascular regression in spontaneously hypertensive rats

Hypertension

Volumn 29, Issue 1 II, 1997, Pages 340-349

  DeBlois, Denis ^b   Tea, Bun Seng ^b   Dam, Than Vinh ^b   Tremblay, Johanne ^b   Hamet, Pavel ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b NONE

Author keywords

angiotensin II; apoptosis; calcium channel antagonist; smooth muscle cell

Indexed keywords

ANTIHYPERTENSIVE AGENT; DNA FRAGMENT; ENALAPRIL; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LOSARTAN; NIFEDIPINE; PROPRANOLOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA MEDIA; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CELL DEATH; CONTROLLED STUDY; DNA CONTENT; DNA SYNTHESIS; DRUG EFFECT; HYPERTENSION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REMISSION; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR SMOOTH MUSCLE;

EID: 0031037546     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.29.1.340     Document Type: Article

References (87)

1. Folkow B. Physiological aspects of primary hypertension. Physiol Rev. 1982;62:347-504.
2. Mulvany MJ. Are vascular abnormalities a primary cause or secondary consequence of hypertension? Hypertension. 1991;18(suppl I): I-52-I-57.
3. Lee RMKW, Smeda JS. Primary versus secondary structural changes of the blood vessels in hypertension. Can J Physiol Pharmacol. 1985;63:392-401.
4. Schiffrin EL. Reactivity of small blood vessels in hypertension: Relation with structural changes. Hypertension. 1992;19(suppl II): II-1-II-9.
5. Heagerty AM, Aalkjaer C, Bund SJ, Korsgaard N, Mulvany MJ. Small artery structure in hypertension: dual processes of remodeling and growth. Hypertension. 1993;21:391-397.
6. Heistad DD, Armstrong ML, Baumbach GL, Faraci FM. Sick vessel syndrome: recovery of atherosclerotic and hypertensive vessels. Hypertension. 1995;26:509-513.
7. Lee RM, Owens GK, Scott-Burden T, Head RJ, Mulvany MJ, Schiffrin EL. Pathophysiology of smooth muscle in hypertension. Can J Physiol Pharmacol. 1995;73:574-584. Review.
8. Folkow B. "Structural factor" in primary and secondary hypertension. Hypertension. 1990;16:89-101.
9. Safar ME, Laurent S. Behaviour of conduit arteries in hypertension. Clin Exp Hypertens. 1993;15:1033-1045. Review.
10. Boudier HAJS, van Bortel LMAB, De Mey JGR. Remodeling of the vascular tree in hypertension: drug effects. Trends Pharmacol Sci. 1990;11:240-245.
11. Mulvany MJ. Determinants of vascular structure. J Cardiovasc Pharmacol. 1992;19(suppl 5):S1-S6.
12. Mulvany MJ. The development and regression of vascular hypertrophy. J Cardiovasc Pharmacol. 1992;19(suppl 2):S22-S27.
13. Safar ME, Levy BI, London GM. Arterial structure in hypertension and the effects of angiotensin converting enzyme inhibition. J Hypertens Suppl. 1992;10:551-557. Review.
14. Owens GK, Schwartz SM. Vascular smooth muscle cell hypertrophy and hyperploidy in the Goldblatt hypertensive rat. Circ Res. 1983; 53:491-501.
15. Yamori Y, Mano M, Nara Y, Horie R. Catecholamine-induced polyploidization in vascular smooth muscle cells. Circulation. 1987; 75(suppl I):I-92-I-95.
16. Owens GK. Control of hypertrophic versus hyperplastic growth of vascular smooth muscle cells. Am J Physiol. 1989;257:H1755-H1765.
17. Walker SV, Hamet P. Enhanced DNA synthesis in heart and kidney of newborn spontaneously hypertensive rats. Hypertension 1986; 8:520-525.
18. Mulvany MJ, Baandrup U, Gundersen HLG. Evidence for hyperplasia in mesenteric resistance vessels of spontaneously hypertensive rats using a three-dimensional dissector. Circ Res. 1985;57:794-800.
19. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239-257.
20. Thompson GB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456-1462.
21. Hamet P, Richard L, Dam T-V, Teiger E, Orlov SN, Gaboury L, Gossard F, Tremblay J. Apoptosis in target organs of hypertension. Hypertension. 1995;26:642-648.
22. Frohlich ED, Sasaki O, Chien Y, Arita M. Changes in cardiovascular mass, left ventricular pumping ability and aortic distensibility after calcium antagonists in Wistar-Kyoto and spontaneously hypertensive rats. J Hypertens. 1992;10:1369-1378.
23. Oddie CJ, Dilley RJ, Bobik A. Long-term angiotensin II antagonism in spontaneously hypertensive rats: effects on blood pressure and cardiovascular amplifiers. Clin Exp Pharmacol Physiol Suppl. 1992; 19:392-395.
24. Igawa T, Ikeno K, Watanabe K, Kimura Y. Dose-related inhibitory effects of the beta-adrenoceptor blocking drug carteolol and propranolol ion cardiac hypertrophy in spontaneously hypertensive rats. Eur J Pharmacol. 1984;104:93-99.
25. Kobayashi H, Sano T, Tarazi RC, Fouad-Tarazi FM. Effects of antihypertensive drugs on heart and resistance vessels. Cardiovasc Res. 1990;24:137-143.
26. Teiger E, Dam TV, Richard L, Wisnewsky C, Tea BS, Gaboury L, Tremblay J, Schwartz K, Hamet P. Apoptosis in pressure overloadinduced heart hypertrophy in the rat. J Clin Invest 1996;97: 2891-2897.
27. Bortner CD, Oldenburg NBE, Cidlowski JA. The role of DNA fragmentation in apoptosis. Trends Cell Biol. 1995;5:21-26.
28. Oberhammer F, Wilson JW, Dive C, Morris ID, Kichman JA, Wakeling AE, Walker PR, Sikorska M. Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J. 1993;12 (9):3679-3684.
29. Cho A, Courtman DW, Langille BL. Apoptosis (programmed cell death) in arteries of the neonatal lamb. Circ Res. 1995;76:168-175.
30. Bennett MR, Evan GI, Newby AC. Deregulated expression of the c-myc oncogene abolishes inhibition of proliferation of rat vascular smooth muscle cells by serum reduction, interferon-gamma, heparin, and cyclic nucleotide analogues and induces apoptosis. Circ Res. 1994;74:525-536.
31. Bennett MR, Evan GI, Schwartz S.M. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest. 1995;95:2266-2274.
32. Miura M, Shu H, Rotello R, Hartwieg EA, Yuan J. Induction of apoptosis in fibroblasts by IL-1 beta-converting enzyme, a mammalian homolog of the C elegans cell death gene ced-3. Cell. 1993; 75:653-660.
33. Orlov SN, Dam TV, Tremblay J, Hamet P. Apoptosis in vascular smooth muscle cells: role of cell shrinkage. Biochem Biophys Res Commun. 1996;221:708-715.
34. Owens GK. Differential effects of antihypertensive drug therapy on vascular smooth muscle cell hypertrophy, hyperploidy, and hyperplasia in the spontaneously hypertensive rat. Circ Res. 1985;56: 525-536.
35. Owens GK. Influence of blood pressure on development of aortic medial smooth muscle hypertrophy in spontaneously hypertensive rats. Hypertension. 1987;9:178-187.
36. Owens GK, Schwartz SM. Alterations in vascular smooth muscle mass in the spontaneously hypertensive rat: role in cellular hypertrophy, hyperploidy, and hyperplasia. Circ Res. 1982;51:280-289.
37. Loeb AL, Bean BL. Antihypertensive drugs inhibit hypertension-associated aortic DNA synthesis in the rat. Hypertension. 1986; 8:1135-1142.
38. Dominiczak AF, Devlin AM, Lee WK, Anderson NH, Bohr DF, Reid JL. Vascular smooth muscle polyploidy and cardiac hypertrophy in genetic hypertension. Hypertension. 1996;27:752-759.
39. Scott-Burden T, Resink TJ, Baur U, Burgin M, Buhler FR. Epidermal growth factor responsiveness in smooth muscle cells from hypertensive and normotensive rats. Hypertension. 1989;13:295-304.
40. Hamet P, Hadrava V, Kruppa U, Tremblay J. Transforming growth factor β1 expression and effect in aortic smooth muscle cells from spontaneously hypertensive rats. Hypertension. 1991;17:896-901.
41. Hamet P, Hadrava V, Kruppa U, Tremblay J. Vascular smooth muscle cell hyper-responsiveness to growth factors in hypertension. J Hypertens Suppl. 1988;6:S36-S39.
42. Hadrava V, Tremblay J, Sekaly RP, Hamet P. Accelerated entry of aortic smooth muscle cells from spontaneously hypertensive rats into the S phase of the cell cycle. Biochem Cell Biol. 1992;70:599-604.
43. Conyers RB, Kwan CY, Lee RM. Alterations in beta-adrenoceptors and polyploidy in cultured aortic smooth muscle cells from different age groups of spontaneously hypertensive rats and Wistar-Kyoto rats. J Hypertens. 1995;13:507-515.
44. Lee RM, Conyers RB, Kwan CY. Incidence of multinucleated and polyploid aortic smooth muscle cells cultured from different age groups of spontaneously hypertensive rats. Can J Physiol Pharmacol. 1992;70:1496-1501.
45. Hamet P, deBlois D, Dam T-V, Richard L, Teiger E, Tea B-S, Orlov SN, Tremblay J. Apoptosis and vascular wall remodeling in hypertension. Can J Physiol Pharmacol. 1996;74:850-861.
46. Hamet P, Moreau P, Dam T-V, Orlov SN, Tea B-S, deBlois D, Tremblay J. The time window of apoptosis: a new component in the therapeutic strategy for cardiovascular remodeling. J Hypertens. 1996;14(suppl 5):S65-S70.
47. Leszczynski D, Shao Y, Luokkamaki M, Foegh ML. Apoptosis of vascular smooth muscle cells: protein kinase C and oncoprotein Bcl-2 are involved in regulation of apoptosis in non-transformed rat vascular smooth muscle cells. Am J Pathol. 1994;145:1265-1270.
48. Soltis EE. Alterations in vascular structure and function after short-term losartan treatment in spontaneously hypertensive rats. J Pharmacol Exp Ther. 1993;266:642-646.
49. Ferrante F, Abbate F, Ciriaco E, Laura R, Amenta F. Influence of isradipine treatment on the morphology of the aorta in spontaneously hypertensive rats. J Hypertens. 1994;12:523-531.
50. Benetos A, Albaladejo P, Levy BI, Safar ME. Acute and long-term effects of angiotensin converting enzyme inhibition on larger arteries and cardiac hypertrophy: mechanical and structural parameters. J Hypertens Suppl. 1994;12:S21-S29.
51. Safar ME, Levy BI. Mechanical function and histological structure of the arterial wall. The response to antihypertensive treatment. Drugs. 1993;46(suppl 2):68-74. Review.
52. Albaladejo P, Bouaziz H, Duriez M, Gohlke P, Levy BI, Safar ME, Benetos A. Angiotensin-converting enzyme inhibition prevents the increase in aortic collagen in rats. Hypertension. 1994;23:74-82.
53. Safar ME, Frohlich ED. The arterial system in hypertension: a prospective view. Hypertension. 1995;26:10-14.
54. Yamori Y, Tarazi RC, Ooshima A. Effect of beta-receptor-blocking agents on cardiovascular structural changes in spontaneous and noradrenaline-induced hypertension in rats. Clin Sci. 1980;59:457s-460s.
55. Benetos A, Poitevin P, Prost PL, Safar ME, Levy BI. Life survival and cardiovascular structures following selective beta-blockade in spontaneously hypertensive rats. Am J Hypertens. 1994;7:186-192.
56. Contard F, Glukhova M, Marotte F, Narcisse G, Schatz C, Swynghedauw B, Guez D, Samuel JL, Rappaport L. Diuretic effects on cardiac hypertrophy in the stroke prone spontaneously hypertensive rat. Cardiovasc Res. 1993;27:429-434.
57. Bochaton-Piallat ML, Gabbiani F, Redard M, Desmoulière A, Gabbiani G. Apoptosis participates in cellularity regulation during rat aortic intimal thickening. Am J Pathol. 1995;146:1059-1064.
58. Han DK, Haudenschild CC, Hong MK, Tinkle BT, Leon MB, Liau G. Evidence for apoptosis in human atherogenesis and in a rat vascular injury model. Am J Pathol. 1995;147:267-277.
59. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury: smooth muscle growth in the absence of endothelium. Lab Invest. 1983;49:327-333.
60. Devlin AM, Gordon JF, Davidson AO, Clark JS, Hamilton CA Morton JJ, Campbell AM, Reid JL, Dominiczak AF. The effects of perindopril on vascular smooth muscle polyploidy in stroke-prone spontaneously hypertensive rats. J Hypertens. 1995;13:211-218.
61. Owens GK, Reidy MA. Hyperplastic growth response of vascular smooth muscle cells following induction of acute hypertension in rats by aortic coarctation. Circ Res. 1985;57:695-705.
62. Mulvany MJ, Baumbach GL, Aalkjaer C, Heagerty AM, Korsgaard N, Schiffrin EL, Heistad DD. Vascular remodeling. Hypertension. 1996;28:505-506.
63. Fukuo K, Hata S, Suhara T, Nakahashi T, Shinto Y, Tsujimoto Y, Morimoto S, Ogihara T. Nitric oxide induces upregulation of Fas antigen and apoptosis in vascular smooth muscle cells. Hypertension. 1996;27:823-826.
64. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle: cell growth response to angiotensin II. J Clin Invest. 1993;91:2268-2274.
65. Naftilan AJ, Pratt RE, Dzau VJ. Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83: 1419-1424.
66. Bennett MR, Evan GI, Newby AC. Deregulated expression of the c-myc oncogene abolishes inhibition of proliferation of rat vascular smooth muscle cells by serum reduction, interferon-γ, heparin, and cyclic nucleotide analogues and induces apoptosis. Circ Res. 1994;74:525-536.
67. Bennett MR, Evan GI, Schwartz SM. Apoptosis of rat vascular smooth muscle cells is regulated by p53 dependent and independent pathways. Circ Res. 1995;77:266-273.
68. Jackson CL, Schwartz SM. Pharmacology of smooth muscle cell replication. Hypertension. 1992;20:713-736.
69. Hamet P, Orlov SN, Tremblay J. Dissociation of DNA synthesis and apoptosis in vascular smooth muscle cells. Hypertension. 1996; 28:529. Abstract.
70. deBlois D, Lombardi DM, Su JE, Clowes AW, Schwartz SM, Giachelli CM. Angiotensin II induction of osteopontin expression and DNA synthesis in rat arteries. Hypertension. 1996;28:1055-1063.
71. 3, antagonists promote tumor regression by inducing apoptosis in angiogenic blood vessels. Cell. 1994;79:1157-1164.
72. Meredith J, Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell. 1993;4:953-961.
73. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JAM, Smith RD. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993;45:205-251.
74. Ichiki T, Labosky PA, Shiota C, Okuyama S, Imagawa Y, Fogo A, Niimura F, Ichikawa I, Hogan BL, Inagami T. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature. 1995;377:748-750.
75. Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature. 1995;377:744-747.
76. Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt RE, Dzau VJ. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci U S A. 1995;92:10663-10667.
77. Yamada T, Horiuchi M, Dzau VJ. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci U S A. 1996;93:156-160.
78. Tanaka M, Ohmshi J, Ozawa Y, Sugimoto M, Usuki S, Naruse M, Murakami K, Miyazaki H. Characterization of angiotensin II receptor type 2 during differentiation and apoptosis of rat ovarian cultured granulosa cells. Biochem Biophys Res Commun. 1995;207:593-598.
79. Bao G, Gohlke P, Qadri F, Unger T. Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril. Hypertension. 1992;20:74-79.
80. Furberg CD, Patsy BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326-1331.
81. Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P, Havlik RJ. Do calcium channel blockers increase the risk of cancer? Am J Hypertens. 1996;9:695-699.
82. Epstein M. Calcium antagonists: still appropriate as first line antihypertensive agents. Am J Hypertens. 1996;9:110-121.
83. Hamet P. Cancer and hypertension: an unresolved issue. Hypertension. 1996;28:321-324.
84. Schiffrin EL, Deng LY, Larochelle P. Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I-converting enzyme inhibitor. Comparison with effects of a β-blocker. Am J Hypertens. 1995; 8:229-236.
85. Thybo NK, Stephens N, Cooper A, Aalkjaer C, Heagerty AM, Mulvany MJ. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension. 1995;25:474-481.
86. Schiffrin EL, Deng LY, Structure and function of resistance arteries of hypertensive patients treated with a beta blocker or a calcium channel antagonist. J Hypertens.
87. Daemen MJAP, DeMey JGR. Regional heterogeneity of arterial structural changes. Hypertension. 1995;25:464-473.